EndoCyclic Therapeutics (formerly known as Endomet Biosciences) is a biopharmaceutical company engaged in the development of the first non-hormone therapeutic for the highly painful disease of endometriosis. Afflicting some 10% of women worldwide, endometriosis is the primary cause of infertility and disability among women in the reproductive years. Primarily perhaps due to the lack of effective treatment options, the disease is probably as the most overlooked womens health issues. The focus of the EndoCyclic Therapeutics' team is to bring a solution to the millions of women suffering from endometriosis and to achieve a better awareness of this important womens health issue.
